Business Wire

NY-DUNNHUMBY

14.1.2019 14:02:10 CET | Business Wire | Press release

Share
dunnhumby Launches Media Business, Powered by Customer Data Science, that Connects Retailers and Brands to Customers Along the Entire Customer Journey

NRF 2019: Retail’s Big Show – dunnhumby today introduced dunnhumby media , offering a unique combination of cross-channel media, data science and partnerships that connects retailers and brands to customers, from browsing to buying. dunnhumby media activates retailer data assets to engage consumers with personalized communications along the entire customer journey, wherever they are. Powered by dunnhumby’s customer data science, the media solution helps advertisers grow customer loyalty and enables retailers to monetize their owned media for measurable sales growth.

“Data is fueling the new retail media ecosystem and has become one of the most valuable and critical business assets that helps connect in-store and online customer experiences and behaviors,” said Jérôme Cochet, Global Managing Director, Media for dunnhumby. “With dunnhumby media, retailers can leverage their rich data assets and owned media properties. Advertisers gain highly relevant access to consumers based on world-class customer data science. And most importantly, the customer benefits by receiving compelling offers and personalized communications.”

Case Study: Nestle and Tesco

Nestle partnered with dunnhumby media to promote the launch of a new on-pack promotion to Tesco customers across owned and paid channels – in-store, mobile, online and out-of-home. Working closely together with Nestle, Tesco and a range of partners, dunnhumby media created an insight-driven, multi-channel media plan that reached 5.8 million customers and resulted in an 11 percent overall increase in sales. At the store level, stores with point of sale (POS) and JCD digital screens generated 33 percent sales increase versus 15 percent sales increase in stores with POS screens only.

For retailers, key benefits of dunnhumby media include:

  • Delivers more efficient and effective customer engagement across retailer-owned and paid offsite media channels
  • Increases the value of the retailer’s owned media by building incremental profit of 30 to 40 percent through in-store media (POS, digital screens, experiential); digital media (eCommerce, mobile app); and direct media (personalized email and coupons, customer magazine)
  • Monetizes first-party data and activates other data assets to grow sales and profit

For advertisers, key benefits of dunnhumby media include:

  • Activates personalized, brand-safe campaigns across channels with closed-loop reporting and actionable results
  • Improves customer engagement and builds loyalty by planning and activating advertising more efficiently across offline and digital media channels, including programmatic media
  • Increases the return on advertising media investments

“Retailers have been challenged with eroding profit margins from digital disruption and new market entrants, and tough economic times are likely ahead,” said Cochet. “Retail media presents an untapped opportunity for retailers to connect brands with consumers, create meaningful engagements and grow alternative revenue streams for sustainable, profitable growth.”

For more information on dunnhumby media, visit dunnhumby’s booth at NRF 2019 (#2073) or visit https://www.dunnhumby.com/solutions/media . Additional dunnhumby media case studies and other information are available in the first issue of dunnhumby media’s Food Fresh magazine: http://bit.ly/2Ha2qLl .

About dunnhumby

dunnhumby is the global leader in Customer Data Science, empowering businesses everywhere to compete and thrive in the modern data-driven economy. We always put the Customer First.

Our mission: to enable businesses to grow and reimagine themselves by becoming advocates and champions for their Customers. With deep heritage and expertise in retail – one of the world’s most competitive markets, with a deluge of multi-dimensional data – dunnhumby today enables businesses all over the world, across industries, to be Customer First.

The dunnhumby Customer Data Science Platform is our unique mix of technology, software and consulting, enabling businesses to increase revenue and profits by delivering exceptional experiences for their Customers – in-store, offline and online. dunnhumby employs over 2,500 experts in offices throughout Europe, Asia, Africa, and the Americas working for transformative, iconic brands such as Tesco, Coca-Cola, Meijer, Procter & Gamble, L’Oréal.

Contact:

Theresa Smith Silicon Valley Story Lab theresa@siliconvalleystorylab.com +1-818-681-6456

Link:

ClickThru

Social Media:

https://www.facebook.com/dunnhumby

https://www.facebook.com/dunnhumby/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye